查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786353

全球电脑刀市场

CyberKnife
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 282 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球电脑刀市场规模将达 17 亿美元

全球电脑刀市场规模预计在2024年达到6.184亿美元，预计在分析期内（2024-2030年）将以18.5%的复合年增长率增长，到2030年将达到17亿美元。肿瘤学应用是本报告分析的细分市场之一，预计其复合年增长率将达到20.0%，到分析期结束时将达到11亿美元。在分析期内，肿瘤学应用细分市场的复合年增长率预计将达到17.3%。

美国市场规模估计为 1.685 亿美元，中国市场预计复合年增长率为 24.5%

美国电脑刀市场规模预计2024年达到1.685亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到3.875亿美元，在2024-2030年的分析期内，复合年增长率为24.5%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为13.6%和16.8%。在欧洲，预计德国市场的复合年增长率约为14.8%。

全球电脑刀市场－主要趋势与市场驱动因素摘要

电脑刀为何获得精准放射治疗的认可？

电脑刀是一款尖端机器人放射线手术系统，透过提供非侵入性、高精度的放射治疗，彻底改变了癌症治疗。与传统放射技术不同， 电脑刀采用即时影像引导和机器人技术，以亚毫米级的精度瞄准肿瘤，最大限度地减少对周围健康组织的损伤。这使得它成为治疗复杂癌症（包括脑癌、前列腺癌、肺癌、脊髓癌和胰腺癌）的重要工具。

全球癌症发生率的上升推动了对先进放射治疗解决方案的需求，而电脑刀已成为寻求无痛门诊治疗的患者的首选方案。 CyberKnife 能够适应患者移动，尤其是在肺癌和前列腺癌治疗中，从而提高治疗效果和患者舒适度。此外，立体定位放射治疗 (SBRT) 和立体定位放射线手术(SRS) 的日益普及也推动了电脑刀系统在全球领先肿瘤中心的整合。

电脑刀系统的最新技术进步是什么？

机器人放射线手术的持续创新显着提升了电脑刀的功能，使治疗更加精准、高效和安全。其中最显着的进步之一是整合了人工智慧肿瘤追踪技术，可根据患者运动即时调整放射束。这对于治疗肺部等运动器官中的肿瘤尤其有益，因为呼吸运动会影响标靶精确度。

另一个突破是新一代线性加速器（linacs）的研发，该技术可在更短的治疗时间内提供更高的剂量，从而减少所需的治疗次数。此外，MRI引导放射放射线手术和自适应放射治疗等先进影像技术正与电脑刀系统整合，以优化治疗计划并改善临床疗效。云端基础的治疗计划和远端监控功能也在不断扩展，使肿瘤内科医生能够远端协作并调整治疗通讯协定。

市场趋势和医疗保健政策如何影响电脑刀 的采用？

医疗保健趋势的演变正在影响着电脑刀的普及，包括转向非侵入性癌症治疗、更加重视以患者为中心的护理以及放射线手术保险覆盖范围的扩大。新兴市场医疗基础设施的不断扩张也促进了电脑刀的普及，医院纷纷投资尖端肿瘤治疗解决方案，以满足日益增长的癌症治疗需求。

美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构不断更新其指南，以确保放射治疗系统的安全性和有效性。这些法规迫使电脑刀製造商加强品管，开发基于人工智慧的安全机制，并提高对国际放射治疗标准的合规性。此外，越来越多支持电脑刀有效性的临床研究巩固了其作为领先放射线手术解决方案的地位。

推动电脑刀市场成长的因素有哪些？

机器人放射线手术的进步、癌症发病率的上升以及人们对非侵入性治疗方法日益增长的偏好推动了电脑刀市场的成长。随着越来越多的医疗机构认识到精准放射治疗的益处，已开发国家和开发中国家对电脑刀系统的投资都在增加。

神经外科、整形外科和儿科放射治疗正在使用电脑刀进行更精准、更微创的治疗。患者和肿瘤科医师对电脑刀的认知度不断提高，也推动了市场的成长，尤其是在治疗结果持续显示存活率提高和副作用减少的情况下。此外，医疗保健提供者与放射治疗技术公司之间的伙伴关係正在推动创新，提高可及性，并确保电脑刀治疗通讯协定的持续改进。

部分

用途（癌症用途、肿瘤学用途、血管畸形用途、其他用途）；最终用途（医院最终用途、门诊病人设施最终用途、研究和製造最终用途）

受访公司范例

  • Apollo Hospitals
  • Azienda Ospedaliera di Padova
  • Centre Oscar Lambret
  • Charite-Universitatsmedizin Berlin
  • Clinica Universidad de Navarra
  • CyberKnife Center at Mercy Hospital
  • CyberKnife Center Munich
  • CyberKnife Center of Miami
  • CyberKnife Center of Southern California
  • Hopital Europeen Georges-Pompidou
  • Instituto de Radiocirugia CyberKnife IRCA
  • National Cancer Centre Singapore
  • Ospedale San Raffaele
  • Providence Swedish Radiosurgery Center
  • Samsung Medical Center
  • Stanford Health Care
  • Tata Memorial Hospital
  • The Harley Street Clinic
  • Universitatsklinikum Heidelberg
  • University College Hospital London

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，其中包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP30332

Global CyberKnife Market to Reach US$1.7 Billion by 2030

The global market for CyberKnife estimated at US$618.4 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 18.5% over the analysis period 2024-2030. Cancer Application, one of the segments analyzed in the report, is expected to record a 20.0% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Tumor Application segment is estimated at 17.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.5 Million While China is Forecast to Grow at 24.5% CAGR

The CyberKnife market in the U.S. is estimated at US$168.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$387.5 Million by the year 2030 trailing a CAGR of 24.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global CyberKnife Market - Key Trends & Growth Drivers Summarized

Why Is CyberKnife Gaining Recognition in Precision Radiation Therapy?

CyberKnife, a state-of-the-art robotic radiosurgery system, has revolutionized cancer treatment by offering non-invasive, high-precision radiation therapy. Unlike traditional radiation techniques, CyberKnife utilizes real-time image guidance and robotic technology to target tumors with sub-millimeter accuracy, minimizing damage to surrounding healthy tissues. This has made it an essential tool in treating complex cancers, including brain, prostate, lung, spine, and pancreatic tumors.

The rising global cancer burden has intensified the demand for advanced radiotherapy solutions, with CyberKnife emerging as a preferred alternative for patients seeking pain-free, outpatient-based treatment. Its ability to adapt to patient movement, particularly in lung and prostate cancer cases, enhances treatment efficacy and patient comfort. Additionally, the growing adoption of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) has propelled the integration of CyberKnife systems in leading oncology centers worldwide.

What Are the Latest Technological Advancements in CyberKnife Systems?

Continuous innovation in robotic radiosurgery has significantly improved CyberKnife’s capabilities, enhancing treatment accuracy, efficiency, and safety. One of the most notable advancements is the integration of AI-driven tumor tracking, allowing real-time adjustments to radiation beams based on patient movement. This is particularly beneficial for treating tumors in mobile organs, such as the lungs, where respiratory motion can affect targeting precision.

Another breakthrough is the development of next-generation linear accelerators, which deliver higher radiation doses in shorter treatment times, reducing the number of sessions required. Additionally, advanced imaging modalities, including MRI-guided radiosurgery and adaptive radiotherapy, are being integrated with CyberKnife systems to refine treatment planning and improve clinical outcomes. Cloud-based treatment planning and remote monitoring capabilities are also expanding, allowing oncologists to collaborate and adjust treatment protocols remotely.

How Are Market Trends and Healthcare Policies Influencing CyberKnife Adoption?

The adoption of CyberKnife is being shaped by evolving healthcare trends, including the shift toward non-invasive cancer treatments, increased focus on patient-centered care, and growing reimbursement coverage for radiosurgery procedures. The expansion of healthcare infrastructure in emerging markets has also contributed to CyberKnife’s adoption, as hospitals invest in cutting-edge oncology solutions to meet rising cancer treatment demands.

Regulatory agencies, including the FDA and the European Medicines Agency (EMA), are continuously updating guidelines to ensure the safety and efficacy of radiation therapy systems. These regulations have driven CyberKnife manufacturers to enhance quality control, develop AI-driven safety mechanisms, and improve compliance with international radiation therapy standards. Additionally, the rising number of clinical studies supporting CyberKnife’s efficacy is strengthening its position as a leading radiosurgery solution.

What Is Driving the Growth of the CyberKnife Market?

The growth in the CyberKnife market is driven by advancements in robotic radiosurgery, increasing cancer incidence rates, and the growing preference for non-invasive treatment modalities. As more healthcare providers recognize the benefits of precision radiation therapy, investments in CyberKnife systems are expanding across developed and developing regions.

End-use expansion is another key factor, with neurosurgery, orthopedic oncology, and pediatric radiation therapy incorporating CyberKnife for more precise, minimally invasive treatments. The rising awareness of CyberKnife among patients and oncologists is also fueling market growth, particularly as treatment outcomes continue to demonstrate improved survival rates and reduced side effects. Additionally, partnerships between healthcare providers and radiotherapy technology firms are fostering innovation, enhancing accessibility, and ensuring continued advancements in CyberKnife treatment protocols.

SCOPE OF STUDY:

The report analyzes the CyberKnife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Cancer Application, Tumor Application, Vascular Malformation Application, Other Applications); End-Use (Hospitals End-Use, Outpatient Facilities End-Use, Research and Manufacturing End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Apollo Hospitals
  • Azienda Ospedaliera di Padova
  • Centre Oscar Lambret
  • Charite - Universitatsmedizin Berlin
  • Clinica Universidad de Navarra
  • CyberKnife Center at Mercy Hospital
  • CyberKnife Center Munich
  • CyberKnife Center of Miami
  • CyberKnife Center of Southern California
  • Hopital Europeen Georges-Pompidou
  • Instituto de Radiocirugia CyberKnife IRCA
  • National Cancer Centre Singapore
  • Ospedale San Raffaele
  • Providence Swedish Radiosurgery Center
  • Samsung Medical Center
  • Stanford Health Care
  • Tata Memorial Hospital
  • The Harley Street Clinic
  • Universitatsklinikum Heidelberg
  • University College Hospital London

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • CyberKnife - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Globally Fuels Adoption of Non-Invasive Radiosurgical Solutions Like CyberKnife
    • Growing Patient Preference for Precision, Painless, Outpatient Treatments Strengthens CyberKnife Utilization
    • Advancements in Real-Time Tumor Tracking and Adaptive Radiotherapy Enhance Clinical Outcomes
    • OEM Innovation in Image-Guided Robotic Systems Propels CyberKnife Over Conventional Linac Systems
    • Increased Deployment in Private Cancer Care Chains and Specialty Oncology Centers Drives Market Expansion
    • FDA and CE Mark Approvals for Expanded Indications Accelerate Global CyberKnife Adoption
    • Integration With Treatment Planning and AI-Powered Dosimetry Systems Improves Accuracy and Efficiency
    • Growing Use in Intracranial, Spinal, Lung, and Prostate Tumors Broadens Application Scope
    • Rising Referrals From Neurosurgeons and Radiation Oncologists Boost Clinical Awareness and Volume
    • OEM Expansion Into Emerging Markets Supports Access to Robotic Radiosurgery Technology
    • Favorable Reimbursement for Radiosurgery in Developed Markets Enhances Adoption Rates
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CyberKnife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vascular Malformation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Outpatient Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Research & Manufacturing End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION